Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

5 Tech Stocks to Consider: These Nerds Are Full of Surprises!


Companies like these five should keep rolling after recently trouncing earnings estimates.


We're going to miss the earnings season now winding down. It was another quarterly cornucopia -- and by the look of thinning forward estimates, possibly the last one for a while.

The profit procession took the edge off Greece and Italy and Spain, housing and joblessness, protests and political gridlock. Perhaps not entirely coincidentally, the stock market shot up like a rocket.

But now that most reports have come and gone, we're back at the mercy of the news flow and the algorithms.

Qualcomm (QCOM) should do very well today after posting strong numbers last night. But most stocks -- including many that recently blew away estimates -- will trade on risks of a Greek default, rising Italian bond yields, the G20 summit in Cannes, and the European Central Bank decision.

As of the middle of the night, stock futures foretold a beating. [Futures bounced back just before the open on more macro news -- namely, the rumored resignation of Greek Prime Minister George Papandreou -- Editor.]

But who can tell how things will end up? The only certainty these days is that individual stocks, and even entire asset classes, will trade together whether the mode is risk-on or risk-off. Correlations among stocks have seldom been this high. As the indispensable Reformed Broker blog observes, "The market has become One Big Fat F***ing ETF, deal with it."

Joshua Brown's point is that stock picking is pointless while computers flip baskets of stocks with alarming alacrity in response to the latest rumors about Greece.

But for the patient bargain hunter, the correlated volatility can be a blessing: An opportunity to scoop up the cheap stocks that are most likely to outperform over the next couple of years.

Multiple studies have found that stocks serving up big positive earnings surprises can significantly outpace the market, to a degree that might be hard to believe. After all, a big post-earnings pop like Qualcomm is enjoying implies that much of the good news has been priced in.

Yet one 2004 study found that the most extreme earnings beats fuel share gains for three years.

The tail end of an earnings season amid a market correction is an ideal time to go hunting for such future winners. Why? Because while no one wants to pay a 10% premium today for Qualcomm, who now cares that biotech drugmaker Celgene (CELG) delivered $0.07 per share above Wall Street's estimates last week, and raised its annual view, forcing 2012 estimates notably higher?

Certainly not the computers flipping index futures. Celgene shares are down 6% since October 24, yet remain in a clear longer-term uptrend.

Chip maker Intel (INTC) beat estimates by $0.06 a share on October 18 and also provided bullish guidance. Yet annual estimates for this year and next have barely budged.

The stock is down 5% over the last four trading sessions, since breaking out to a three-year high. At nine times forward earnings, with a 3.5% forward dividend yield and a fresh $10 billion buyback, the odds seem good that the breakout isn't done.

Cloud-computing play Citrix Systems (CTXS) also beat by $0.06 last week and exceeded sales expectations as well. The stock popped 17% the next day but has since given back 5%.

These are all names that should do well in the coming months, no matter how sadomasochistic Europe gets. But the 2004 study cited above was focused largely on the smaller companies that beat estimates by a country mile, not six cents.

To capture that sort of momentum, one might look to Spectrum Pharma (SPPI), which reported earnings of $0.34 a share on Friday (versus consensus expectations of $0.10). The $600 million biotech is making a fortune on two cancer drugs, with two more in the pipeline. Revenue has tripled in a year.

The smaller of the company's two approved drugs could get a boost from the Food and Drug Administration on November 20, notes And next year's earnings estimates by the six analysts covering the company could once again prove too low, Briefing notes.

The stock is challenging the all-time high from July and could keep rolling no matter how Greece votes.

Editor's Note: This article was written by Igor Greenwald of MoneyShow.

New! The TechStrat Report by Sean Udall. Sean provides in-depth analysis, strategies and trades across the technology sector. Take a FREE 14 day trial.

Below, find some more great investing and trading content from MoneyShow:

9 Major Plays in the Asian Gas Market
by Peter Staas

Fibonacci Predicts New Gold Rally
by David Banister

Now Everyone Can Trade China's Currency
Larry Schneider

These 3 ETFs Are Very Timely Buys
by Nicholas Vardy

Twitter: @TopProsTopPicks

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.

< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos